European Biotechs Enter the IPO Big League
Genmab's NASDAQ Debut Biggest of 2019
Executive Summary
2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.
You may also be interested in...
Biopharma Should Copy Our Gilead Deal, Says Rising Star Galapagos
$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.
Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Autolus Faces Life After Woodford With New Czech Backer
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.